 | • レポートコード：MRC308GR11511 • 出版社/出版日：GlobalInfoResearch / 2023年8月12日 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（2-3営業日） • 産業分類：医薬品＆ヘルスケア |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Corporate User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
GlobalInfoResearchの最新の調査によると、世界の末梢作用抗肥満薬の市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。
このレポートは、世界の末梢作用抗肥満薬市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、種類別、用途別に記載されています。
市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。
本レポートの主な目的は次のとおりです。
– 世界および主要国の市場機会の規模を決定するため
– 末梢作用抗肥満薬の成長可能性を評価するため
– 各製品および最終用途市場の将来の成長を予測するため
– 市場に影響を与える競争要因を評価するため
末梢作用抗肥満薬市場は種類と用途によって区分されます。2018年～2029年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。
種類別セグメント
・医療用医薬品、一般用医薬品
用途別セグメント
・病院薬局、小売薬局、オンライン薬局
主要な市場プレーヤー
・Novo Nordisk A/S、Pfizer Inc.、Boehringer Ingelheim International GmbH、KVK Tech Inc.、Gelesis Holdings、Vivus LLC.、Currax Pharmaceuticals LLC、GlaxoSmithKline plc、CHEPLAPHARM Arzneimittel GmbH、Rhythm Pharmaceuticals
地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）
本調査レポートの内容は計15章あります。
・第1章では、末梢作用抗肥満薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な末梢作用抗肥満薬メーカーの企業概要、2019年～2022年までの末梢作用抗肥満薬の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な末梢作用抗肥満薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2018年～2029年までの地域別末梢作用抗肥満薬の販売量、売上、成長性を示しています。
・第5、6章では、2018年～2029年までの末梢作用抗肥満薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域での末梢作用抗肥満薬市場予測を収録しています。
・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。
・第13章では、主要な原材料、主要なサプライヤー、および末梢作用抗肥満薬の産業チェーンを掲載しています。
・第14、15章では、末梢作用抗肥満薬の販売チャネル、販売業者、顧客、調査結果について説明します。
***** 目次(一部) *****
・市場概要
– 末梢作用抗肥満薬の概要
– 種類別分析（2018年vs2022年vs2029年）：医療用医薬品、一般用医薬品
– 用途別分析（2018年vs2022年vs2029年）：病院薬局、小売薬局、オンライン薬局
– 世界の末梢作用抗肥満薬市場規模・予測
– 世界の末梢作用抗肥満薬生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– Novo Nordisk A/S、Pfizer Inc.、Boehringer Ingelheim International GmbH、KVK Tech Inc.、Gelesis Holdings、Vivus LLC.、Currax Pharmaceuticals LLC、GlaxoSmithKline plc、CHEPLAPHARM Arzneimittel GmbH、Rhythm Pharmaceuticals
・メーカー別市場シェア・市場集中度
・地域別市場分析2018年-2029年
・種類別分析2018年-2029年：医療用医薬品、一般用医薬品
・用途別分析2018年-2029年：病院薬局、小売薬局、オンライン薬局
・末梢作用抗肥満薬の北米市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・末梢作用抗肥満薬のヨーロッパ市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・末梢作用抗肥満薬のアジア市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・末梢作用抗肥満薬の南米市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・末梢作用抗肥満薬の中東・アフリカ市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析）
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論
1 Market Overview
1.1 Product Overview and Scope of Peripherally Acting Anti-Obesity Drug
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Peripherally Acting Anti-Obesity Drug Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Prescription Drugs
1.3.3 Non-prescription Drugs
1.4 Market Analysis by Application
1.4.1 Overview: Global Peripherally Acting Anti-Obesity Drug Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital Pharmacies
1.4.3 Retail Pharmacies
1.4.4 Online Pharmacies
1.5 Global Peripherally Acting Anti-Obesity Drug Market Size & Forecast
1.5.1 Global Peripherally Acting Anti-Obesity Drug Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Peripherally Acting Anti-Obesity Drug Sales Quantity (2018-2029)
1.5.3 Global Peripherally Acting Anti-Obesity Drug Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Novo Nordisk A/S
2.1.1 Novo Nordisk A/S Details
2.1.2 Novo Nordisk A/S Major Business
2.1.3 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Product and Services
2.1.4 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Novo Nordisk A/S Recent Developments/Updates
2.2 Pfizer Inc.
2.2.1 Pfizer Inc. Details
2.2.2 Pfizer Inc. Major Business
2.2.3 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Product and Services
2.2.4 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Pfizer Inc. Recent Developments/Updates
2.3 Boehringer Ingelheim International GmbH
2.3.1 Boehringer Ingelheim International GmbH Details
2.3.2 Boehringer Ingelheim International GmbH Major Business
2.3.3 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Product and Services
2.3.4 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Boehringer Ingelheim International GmbH Recent Developments/Updates
2.4 KVK Tech Inc.
2.4.1 KVK Tech Inc. Details
2.4.2 KVK Tech Inc. Major Business
2.4.3 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Product and Services
2.4.4 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 KVK Tech Inc. Recent Developments/Updates
2.5 Gelesis Holdings
2.5.1 Gelesis Holdings Details
2.5.2 Gelesis Holdings Major Business
2.5.3 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Product and Services
2.5.4 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Gelesis Holdings Recent Developments/Updates
2.6 Vivus LLC.
2.6.1 Vivus LLC. Details
2.6.2 Vivus LLC. Major Business
2.6.3 Vivus LLC. Peripherally Acting Anti-Obesity Drug Product and Services
2.6.4 Vivus LLC. Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Vivus LLC. Recent Developments/Updates
2.7 Currax Pharmaceuticals LLC
2.7.1 Currax Pharmaceuticals LLC Details
2.7.2 Currax Pharmaceuticals LLC Major Business
2.7.3 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Product and Services
2.7.4 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Currax Pharmaceuticals LLC Recent Developments/Updates
2.8 GlaxoSmithKline plc
2.8.1 GlaxoSmithKline plc Details
2.8.2 GlaxoSmithKline plc Major Business
2.8.3 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Product and Services
2.8.4 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 GlaxoSmithKline plc Recent Developments/Updates
2.9 CHEPLAPHARM Arzneimittel GmbH
2.9.1 CHEPLAPHARM Arzneimittel GmbH Details
2.9.2 CHEPLAPHARM Arzneimittel GmbH Major Business
2.9.3 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Product and Services
2.9.4 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 CHEPLAPHARM Arzneimittel GmbH Recent Developments/Updates
2.10 Rhythm Pharmaceuticals
2.10.1 Rhythm Pharmaceuticals Details
2.10.2 Rhythm Pharmaceuticals Major Business
2.10.3 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Product and Services
2.10.4 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Rhythm Pharmaceuticals Recent Developments/Updates
3 Competitive Environment: Peripherally Acting Anti-Obesity Drug by Manufacturer
3.1 Global Peripherally Acting Anti-Obesity Drug Sales Quantity by Manufacturer (2018-2023)
3.2 Global Peripherally Acting Anti-Obesity Drug Revenue by Manufacturer (2018-2023)
3.3 Global Peripherally Acting Anti-Obesity Drug Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Peripherally Acting Anti-Obesity Drug by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Peripherally Acting Anti-Obesity Drug Manufacturer Market Share in 2022
3.4.2 Top 6 Peripherally Acting Anti-Obesity Drug Manufacturer Market Share in 2022
3.5 Peripherally Acting Anti-Obesity Drug Market: Overall Company Footprint Analysis
3.5.1 Peripherally Acting Anti-Obesity Drug Market: Region Footprint
3.5.2 Peripherally Acting Anti-Obesity Drug Market: Company Product Type Footprint
3.5.3 Peripherally Acting Anti-Obesity Drug Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Peripherally Acting Anti-Obesity Drug Market Size by Region
4.1.1 Global Peripherally Acting Anti-Obesity Drug Sales Quantity by Region (2018-2029)
4.1.2 Global Peripherally Acting Anti-Obesity Drug Consumption Value by Region (2018-2029)
4.1.3 Global Peripherally Acting Anti-Obesity Drug Average Price by Region (2018-2029)
4.2 North America Peripherally Acting Anti-Obesity Drug Consumption Value (2018-2029)
4.3 Europe Peripherally Acting Anti-Obesity Drug Consumption Value (2018-2029)
4.4 Asia-Pacific Peripherally Acting Anti-Obesity Drug Consumption Value (2018-2029)
4.5 South America Peripherally Acting Anti-Obesity Drug Consumption Value (2018-2029)
4.6 Middle East and Africa Peripherally Acting Anti-Obesity Drug Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2018-2029)
5.2 Global Peripherally Acting Anti-Obesity Drug Consumption Value by Type (2018-2029)
5.3 Global Peripherally Acting Anti-Obesity Drug Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2018-2029)
6.2 Global Peripherally Acting Anti-Obesity Drug Consumption Value by Application (2018-2029)
6.3 Global Peripherally Acting Anti-Obesity Drug Average Price by Application (2018-2029)
7 North America
7.1 North America Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2018-2029)
7.2 North America Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2018-2029)
7.3 North America Peripherally Acting Anti-Obesity Drug Market Size by Country
7.3.1 North America Peripherally Acting Anti-Obesity Drug Sales Quantity by Country (2018-2029)
7.3.2 North America Peripherally Acting Anti-Obesity Drug Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2018-2029)
8.2 Europe Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2018-2029)
8.3 Europe Peripherally Acting Anti-Obesity Drug Market Size by Country
8.3.1 Europe Peripherally Acting Anti-Obesity Drug Sales Quantity by Country (2018-2029)
8.3.2 Europe Peripherally Acting Anti-Obesity Drug Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Peripherally Acting Anti-Obesity Drug Market Size by Region
9.3.1 Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Peripherally Acting Anti-Obesity Drug Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2018-2029)
10.2 South America Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2018-2029)
10.3 South America Peripherally Acting Anti-Obesity Drug Market Size by Country
10.3.1 South America Peripherally Acting Anti-Obesity Drug Sales Quantity by Country (2018-2029)
10.3.2 South America Peripherally Acting Anti-Obesity Drug Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Peripherally Acting Anti-Obesity Drug Market Size by Country
11.3.1 Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Peripherally Acting Anti-Obesity Drug Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Peripherally Acting Anti-Obesity Drug Market Drivers
12.2 Peripherally Acting Anti-Obesity Drug Market Restraints
12.3 Peripherally Acting Anti-Obesity Drug Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Peripherally Acting Anti-Obesity Drug and Key Manufacturers
13.2 Manufacturing Costs Percentage of Peripherally Acting Anti-Obesity Drug
13.3 Peripherally Acting Anti-Obesity Drug Production Process
13.4 Peripherally Acting Anti-Obesity Drug Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Peripherally Acting Anti-Obesity Drug Typical Distributors
14.3 Peripherally Acting Anti-Obesity Drug Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Table 1. Global Peripherally Acting Anti-Obesity Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Peripherally Acting Anti-Obesity Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Novo Nordisk A/S Basic Information, Manufacturing Base and Competitors
Table 4. Novo Nordisk A/S Major Business
Table 5. Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Product and Services
Table 6. Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Novo Nordisk A/S Recent Developments/Updates
Table 8. Pfizer Inc. Basic Information, Manufacturing Base and Competitors
Table 9. Pfizer Inc. Major Business
Table 10. Pfizer Inc. Peripherally Acting Anti-Obesity Drug Product and Services
Table 11. Pfizer Inc. Peripherally Acting Anti-Obesity Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Pfizer Inc. Recent Developments/Updates
Table 13. Boehringer Ingelheim International GmbH Basic Information, Manufacturing Base and Competitors
Table 14. Boehringer Ingelheim International GmbH Major Business
Table 15. Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Product and Services
Table 16. Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Boehringer Ingelheim International GmbH Recent Developments/Updates
Table 18. KVK Tech Inc. Basic Information, Manufacturing Base and Competitors
Table 19. KVK Tech Inc. Major Business
Table 20. KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Product and Services
Table 21. KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. KVK Tech Inc. Recent Developments/Updates
Table 23. Gelesis Holdings Basic Information, Manufacturing Base and Competitors
Table 24. Gelesis Holdings Major Business
Table 25. Gelesis Holdings Peripherally Acting Anti-Obesity Drug Product and Services
Table 26. Gelesis Holdings Peripherally Acting Anti-Obesity Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Gelesis Holdings Recent Developments/Updates
Table 28. Vivus LLC. Basic Information, Manufacturing Base and Competitors
Table 29. Vivus LLC. Major Business
Table 30. Vivus LLC. Peripherally Acting Anti-Obesity Drug Product and Services
Table 31. Vivus LLC. Peripherally Acting Anti-Obesity Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Vivus LLC. Recent Developments/Updates
Table 33. Currax Pharmaceuticals LLC Basic Information, Manufacturing Base and Competitors
Table 34. Currax Pharmaceuticals LLC Major Business
Table 35. Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Product and Services
Table 36. Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Currax Pharmaceuticals LLC Recent Developments/Updates
Table 38. GlaxoSmithKline plc Basic Information, Manufacturing Base and Competitors
Table 39. GlaxoSmithKline plc Major Business
Table 40. GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Product and Services
Table 41. GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. GlaxoSmithKline plc Recent Developments/Updates
Table 43. CHEPLAPHARM Arzneimittel GmbH Basic Information, Manufacturing Base and Competitors
Table 44. CHEPLAPHARM Arzneimittel GmbH Major Business
Table 45. CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Product and Services
Table 46. CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. CHEPLAPHARM Arzneimittel GmbH Recent Developments/Updates
Table 48. Rhythm Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 49. Rhythm Pharmaceuticals Major Business
Table 50. Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Product and Services
Table 51. Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Rhythm Pharmaceuticals Recent Developments/Updates
Table 53. Global Peripherally Acting Anti-Obesity Drug Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 54. Global Peripherally Acting Anti-Obesity Drug Revenue by Manufacturer (2018-2023) & (USD Million)
Table 55. Global Peripherally Acting Anti-Obesity Drug Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 56. Market Position of Manufacturers in Peripherally Acting Anti-Obesity Drug, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 57. Head Office and Peripherally Acting Anti-Obesity Drug Production Site of Key Manufacturer
Table 58. Peripherally Acting Anti-Obesity Drug Market: Company Product Type Footprint
Table 59. Peripherally Acting Anti-Obesity Drug Market: Company Product Application Footprint
Table 60. Peripherally Acting Anti-Obesity Drug New Market Entrants and Barriers to Market Entry
Table 61. Peripherally Acting Anti-Obesity Drug Mergers, Acquisition, Agreements, and Collaborations
Table 62. Global Peripherally Acting Anti-Obesity Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 63. Global Peripherally Acting Anti-Obesity Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 64. Global Peripherally Acting Anti-Obesity Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 65. Global Peripherally Acting Anti-Obesity Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 66. Global Peripherally Acting Anti-Obesity Drug Average Price by Region (2018-2023) & (US$/Unit)
Table 67. Global Peripherally Acting Anti-Obesity Drug Average Price by Region (2024-2029) & (US$/Unit)
Table 68. Global Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 69. Global Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 70. Global Peripherally Acting Anti-Obesity Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 71. Global Peripherally Acting Anti-Obesity Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 72. Global Peripherally Acting Anti-Obesity Drug Average Price by Type (2018-2023) & (US$/Unit)
Table 73. Global Peripherally Acting Anti-Obesity Drug Average Price by Type (2024-2029) & (US$/Unit)
Table 74. Global Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 75. Global Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 76. Global Peripherally Acting Anti-Obesity Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 77. Global Peripherally Acting Anti-Obesity Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 78. Global Peripherally Acting Anti-Obesity Drug Average Price by Application (2018-2023) & (US$/Unit)
Table 79. Global Peripherally Acting Anti-Obesity Drug Average Price by Application (2024-2029) & (US$/Unit)
Table 80. North America Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 81. North America Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 82. North America Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 83. North America Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 84. North America Peripherally Acting Anti-Obesity Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 85. North America Peripherally Acting Anti-Obesity Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 86. North America Peripherally Acting Anti-Obesity Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 87. North America Peripherally Acting Anti-Obesity Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 88. Europe Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 89. Europe Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 90. Europe Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 91. Europe Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 92. Europe Peripherally Acting Anti-Obesity Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 93. Europe Peripherally Acting Anti-Obesity Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 94. Europe Peripherally Acting Anti-Obesity Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 95. Europe Peripherally Acting Anti-Obesity Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 96. Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 97. Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 98. Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 99. Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 100. Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 101. Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 102. Asia-Pacific Peripherally Acting Anti-Obesity Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 103. Asia-Pacific Peripherally Acting Anti-Obesity Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 104. South America Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 105. South America Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 106. South America Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 107. South America Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 108. South America Peripherally Acting Anti-Obesity Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 109. South America Peripherally Acting Anti-Obesity Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 110. South America Peripherally Acting Anti-Obesity Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 111. South America Peripherally Acting Anti-Obesity Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 112. Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 113. Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 114. Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 115. Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 116. Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 117. Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 118. Middle East & Africa Peripherally Acting Anti-Obesity Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 119. Middle East & Africa Peripherally Acting Anti-Obesity Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 120. Peripherally Acting Anti-Obesity Drug Raw Material
Table 121. Key Manufacturers of Peripherally Acting Anti-Obesity Drug Raw Materials
Table 122. Peripherally Acting Anti-Obesity Drug Typical Distributors
Table 123. Peripherally Acting Anti-Obesity Drug Typical Customers
List of Figures
Figure 1. Peripherally Acting Anti-Obesity Drug Picture
Figure 2. Global Peripherally Acting Anti-Obesity Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Peripherally Acting Anti-Obesity Drug Consumption Value Market Share by Type in 2022
Figure 4. Prescription Drugs Examples
Figure 5. Non-prescription Drugs Examples
Figure 6. Global Peripherally Acting Anti-Obesity Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 7. Global Peripherally Acting Anti-Obesity Drug Consumption Value Market Share by Application in 2022
Figure 8. Hospital Pharmacies Examples
Figure 9. Retail Pharmacies Examples
Figure 10. Online Pharmacies Examples
Figure 11. Global Peripherally Acting Anti-Obesity Drug Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 12. Global Peripherally Acting Anti-Obesity Drug Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 13. Global Peripherally Acting Anti-Obesity Drug Sales Quantity (2018-2029) & (K Units)
Figure 14. Global Peripherally Acting Anti-Obesity Drug Average Price (2018-2029) & (US$/Unit)
Figure 15. Global Peripherally Acting Anti-Obesity Drug Sales Quantity Market Share by Manufacturer in 2022
Figure 16. Global Peripherally Acting Anti-Obesity Drug Consumption Value Market Share by Manufacturer in 2022
Figure 17. Producer Shipments of Peripherally Acting Anti-Obesity Drug by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 18. Top 3 Peripherally Acting Anti-Obesity Drug Manufacturer (Consumption Value) Market Share in 2022
Figure 19. Top 6 Peripherally Acting Anti-Obesity Drug Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Global Peripherally Acting Anti-Obesity Drug Sales Quantity Market Share by Region (2018-2029)
Figure 21. Global Peripherally Acting Anti-Obesity Drug Consumption Value Market Share by Region (2018-2029)
Figure 22. North America Peripherally Acting Anti-Obesity Drug Consumption Value (2018-2029) & (USD Million)
Figure 23. Europe Peripherally Acting Anti-Obesity Drug Consumption Value (2018-2029) & (USD Million)
Figure 24. Asia-Pacific Peripherally Acting Anti-Obesity Drug Consumption Value (2018-2029) & (USD Million)
Figure 25. South America Peripherally Acting Anti-Obesity Drug Consumption Value (2018-2029) & (USD Million)
Figure 26. Middle East & Africa Peripherally Acting Anti-Obesity Drug Consumption Value (2018-2029) & (USD Million)
Figure 27. Global Peripherally Acting Anti-Obesity Drug Sales Quantity Market Share by Type (2018-2029)
Figure 28. Global Peripherally Acting Anti-Obesity Drug Consumption Value Market Share by Type (2018-2029)
Figure 29. Global Peripherally Acting Anti-Obesity Drug Average Price by Type (2018-2029) & (US$/Unit)
Figure 30. Global Peripherally Acting Anti-Obesity Drug Sales Quantity Market Share by Application (2018-2029)
Figure 31. Global Peripherally Acting Anti-Obesity Drug Consumption Value Market Share by Application (2018-2029)
Figure 32. Global Peripherally Acting Anti-Obesity Drug Average Price by Application (2018-2029) & (US$/Unit)
Figure 33. North America Peripherally Acting Anti-Obesity Drug Sales Quantity Market Share by Type (2018-2029)
Figure 34. North America Peripherally Acting Anti-Obesity Drug Sales Quantity Market Share by Application (2018-2029)
Figure 35. North America Peripherally Acting Anti-Obesity Drug Sales Quantity Market Share by Country (2018-2029)
Figure 36. North America Peripherally Acting Anti-Obesity Drug Consumption Value Market Share by Country (2018-2029)
Figure 37. United States Peripherally Acting Anti-Obesity Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 38. Canada Peripherally Acting Anti-Obesity Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Mexico Peripherally Acting Anti-Obesity Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Europe Peripherally Acting Anti-Obesity Drug Sales Quantity Market Share by Type (2018-2029)
Figure 41. Europe Peripherally Acting Anti-Obesity Drug Sales Quantity Market Share by Application (2018-2029)
Figure 42. Europe Peripherally Acting Anti-Obesity Drug Sales Quantity Market Share by Country (2018-2029)
Figure 43. Europe Peripherally Acting Anti-Obesity Drug Consumption Value Market Share by Country (2018-2029)
Figure 44. Germany Peripherally Acting Anti-Obesity Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. France Peripherally Acting Anti-Obesity Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. United Kingdom Peripherally Acting Anti-Obesity Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. Russia Peripherally Acting Anti-Obesity Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Italy Peripherally Acting Anti-Obesity Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Quantity Market Share by Type (2018-2029)
Figure 50. Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Quantity Market Share by Application (2018-2029)
Figure 51. Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Quantity Market Share by Region (2018-2029)
Figure 52. Asia-Pacific Peripherally Acting Anti-Obesity Drug Consumption Value Market Share by Region (2018-2029)
Figure 53. China Peripherally Acting Anti-Obesity Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Japan Peripherally Acting Anti-Obesity Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Korea Peripherally Acting Anti-Obesity Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. India Peripherally Acting Anti-Obesity Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Southeast Asia Peripherally Acting Anti-Obesity Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Australia Peripherally Acting Anti-Obesity Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. South America Peripherally Acting Anti-Obesity Drug Sales Quantity Market Share by Type (2018-2029)
Figure 60. South America Peripherally Acting Anti-Obesity Drug Sales Quantity Market Share by Application (2018-2029)
Figure 61. South America Peripherally Acting Anti-Obesity Drug Sales Quantity Market Share by Country (2018-2029)
Figure 62. South America Peripherally Acting Anti-Obesity Drug Consumption Value Market Share by Country (2018-2029)
Figure 63. Brazil Peripherally Acting Anti-Obesity Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. Argentina Peripherally Acting Anti-Obesity Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Quantity Market Share by Type (2018-2029)
Figure 66. Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Quantity Market Share by Application (2018-2029)
Figure 67. Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Quantity Market Share by Region (2018-2029)
Figure 68. Middle East & Africa Peripherally Acting Anti-Obesity Drug Consumption Value Market Share by Region (2018-2029)
Figure 69. Turkey Peripherally Acting Anti-Obesity Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 70. Egypt Peripherally Acting Anti-Obesity Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Saudi Arabia Peripherally Acting Anti-Obesity Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. South Africa Peripherally Acting Anti-Obesity Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Peripherally Acting Anti-Obesity Drug Market Drivers
Figure 74. Peripherally Acting Anti-Obesity Drug Market Restraints
Figure 75. Peripherally Acting Anti-Obesity Drug Market Trends
Figure 76. Porters Five Forces Analysis
Figure 77. Manufacturing Cost Structure Analysis of Peripherally Acting Anti-Obesity Drug in 2022
Figure 78. Manufacturing Process Analysis of Peripherally Acting Anti-Obesity Drug
Figure 79. Peripherally Acting Anti-Obesity Drug Industrial Chain
Figure 80. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 81. Direct Channel Pros & Cons
Figure 82. Indirect Channel Pros & Cons
Figure 83. Methodology
Figure 84. Research Process and Data Source
